[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Impact of BMI on In-Hospital Outcomes in Colorectal Cancer Patients",
    "section": "",
    "text": "Reference Papers:\n\nSalman et al. 2024\nPersaud et al.2019\nSreenivasan et al. 2022\n\nStudy Objective: Examine the impact of body mass index (BMI) on outcomes among inpatient admissions with colorectal cancer.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with colorectal cancer.\nBMI Categories:\n\nUnderweight: BMI ≤19.9 kg/m²\nNormal Weight: BMI 20.0 to 24.9 kg/m²\nOverweight: BMI 25.0 to 29.9 kg/m²\nClass I Obesity: BMI 30.0 to 34.9 kg/m²\nClass II Obesity: BMI 35.0 to 39.9 kg/m²\nClass III Obesity: BMI ≥40.0 kg/m²\n\nOutcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of BMI categories with in-hospital mortality and length of stay, respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance, hospital region, hospital bedsize, hospital location, and teaching status.\nMedical History: Cardiac arrhythmia, Anemia, Cancer, Cerebrovascular disease, Chronic kidney disease, Chronic obstructive pulmonary disease, Diabetes, Dementia, Heart failure, Hypertension, Hyperlipidemia, Myocardial infarction, Peripheral vascular disease, Rheumatoid disease, Valvular heart disease\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Impact of BMI on In-Hospital Outcomes in Colorectal Cancer Patients",
    "section": "",
    "text": "Reference Papers:\n\nSalman et al. 2024\nPersaud et al.2019\nSreenivasan et al. 2022\n\nStudy Objective: Examine the impact of body mass index (BMI) on outcomes among inpatient admissions with colorectal cancer.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with colorectal cancer.\nBMI Categories:\n\nUnderweight: BMI ≤19.9 kg/m²\nNormal Weight: BMI 20.0 to 24.9 kg/m²\nOverweight: BMI 25.0 to 29.9 kg/m²\nClass I Obesity: BMI 30.0 to 34.9 kg/m²\nClass II Obesity: BMI 35.0 to 39.9 kg/m²\nClass III Obesity: BMI ≥40.0 kg/m²\n\nOutcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of BMI categories with in-hospital mortality and length of stay, respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance, hospital region, hospital bedsize, hospital location, and teaching status.\nMedical History: Cardiac arrhythmia, Anemia, Cancer, Cerebrovascular disease, Chronic kidney disease, Chronic obstructive pulmonary disease, Diabetes, Dementia, Heart failure, Hypertension, Hyperlipidemia, Myocardial infarction, Peripheral vascular disease, Rheumatoid disease, Valvular heart disease\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "Impact of BMI on In-Hospital Outcomes in Colorectal Cancer Patients",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 204,3201\nNormal weight (BMI 20.0-24.9kg/m²) N = 38,2251\nUnderweight (BMI ≤19.9kg/m²) N = 49,6751\nOverweight (BMI 25.0-29.9kg/m²) N = 27,2951\nClass I obesity (BMI 30.0-34.9kg/m²) N = 34,0751\nClass II obesity (BMI 35.0-39.9kg/m²) N = 23,4651\nClass III obesity (BMI ≥40.0kg/m²) N = 31,5851\np-value2\n\n\n\n\nAge, y\n65 (56, 74)\n67 (58, 77)\n67 (57, 77)\n67 (57, 77)\n65 (55, 74)\n62 (53, 71)\n61 (52, 69)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n99,600 (49%)\n15,915 (42%)\n25,165 (51%)\n11,945 (44%)\n15,865 (47%)\n12,085 (52%)\n18,625 (59%)\n\n\n\n\n    Male\n104,715 (51%)\n22,310 (58%)\n24,505 (49%)\n15,350 (56%)\n18,210 (53%)\n11,380 (48%)\n12,960 (41%)\n\n\n\n\nRace\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Asian or Pacific Islander\n6,180 (3.1%)\n1,560 (4.2%)\n2,845 (5.9%)\n735 (2.7%)\n515 (1.5%)\n235 (1.0%)\n290 (0.9%)\n\n\n\n\n    Black\n31,865 (16%)\n6,160 (16%)\n9,190 (19%)\n3,635 (14%)\n4,250 (13%)\n3,325 (14%)\n5,305 (17%)\n\n\n\n\n    Hispanic\n18,820 (9.4%)\n3,905 (10%)\n3,830 (7.9%)\n3,165 (12%)\n3,510 (11%)\n2,145 (9.3%)\n2,265 (7.4%)\n\n\n\n\n    Native American\n1,035 (0.5%)\n150 (0.4%)\n225 (0.5%)\n105 (0.4%)\n205 (0.6%)\n145 (0.6%)\n205 (0.7%)\n\n\n\n\n    Other\n5,165 (2.6%)\n1,170 (3.1%)\n1,460 (3.0%)\n685 (2.6%)\n775 (2.3%)\n490 (2.1%)\n585 (1.9%)\n\n\n\n\n    White\n136,845 (68%)\n24,530 (65%)\n31,065 (64%)\n18,480 (69%)\n24,010 (72%)\n16,635 (72%)\n22,125 (72%)\n\n\n\n\nIncome quartile\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    $1 - $51,999\n58,360 (29%)\n10,890 (29%)\n14,400 (30%)\n7,420 (28%)\n9,175 (27%)\n6,705 (29%)\n9,770 (31%)\n\n\n\n\n    $52,000 - $65,999\n53,430 (27%)\n9,305 (25%)\n12,735 (26%)\n7,070 (26%)\n8,785 (26%)\n6,455 (28%)\n9,080 (29%)\n\n\n\n\n    $66,000 - $87,999\n48,310 (24%)\n8,860 (24%)\n11,145 (23%)\n6,620 (25%)\n8,405 (25%)\n5,750 (25%)\n7,530 (24%)\n\n\n\n\n    $88,000 or more\n40,690 (20%)\n8,355 (22%)\n10,425 (21%)\n5,755 (21%)\n7,090 (21%)\n4,245 (18%)\n4,820 (15%)\n\n\n\n\nInsurance payer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Medicaid\n26,420 (13%)\n5,365 (14%)\n7,610 (15%)\n3,310 (12%)\n3,510 (10%)\n2,440 (10%)\n4,185 (13%)\n\n\n\n\n    Medicare\n108,820 (53%)\n21,355 (56%)\n28,590 (58%)\n15,350 (56%)\n17,420 (51%)\n10,985 (47%)\n15,120 (48%)\n\n\n\n\n    Other\n10,415 (5.1%)\n2,215 (5.8%)\n2,665 (5.4%)\n1,310 (4.8%)\n1,710 (5.0%)\n1,070 (4.6%)\n1,445 (4.6%)\n\n\n\n\n    Private\n58,500 (29%)\n9,240 (24%)\n10,770 (22%)\n7,315 (27%)\n11,435 (34%)\n8,935 (38%)\n10,805 (34%)\n\n\n\n\nNo. of comorbidities\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n0.006\n\n\n    No comorbidities\n250 (0.1%)\n25 (&lt;0.1%)\n40 (&lt;0.1%)\n20 (&lt;0.1%)\n55 (0.2%)\n35 (0.1%)\n75 (0.2%)\n\n\n\n\n    One comorbidity\n295 (0.1%)\n20 (&lt;0.1%)\n75 (0.2%)\n15 (&lt;0.1%)\n70 (0.2%)\n45 (0.2%)\n70 (0.2%)\n\n\n\n\n    Two or more comorbidities\n203,775 (100%)\n38,180 (100%)\n49,560 (100%)\n27,260 (100%)\n33,950 (100%)\n23,385 (100%)\n31,440 (100%)\n\n\n\n\nCardiac arrhythmia\n44,385 (22%)\n7,905 (21%)\n9,460 (19%)\n6,250 (23%)\n7,310 (21%)\n5,385 (23%)\n8,075 (26%)\n&lt;0.001\n\n\nAnemia\n34,315 (17%)\n7,165 (19%)\n8,780 (18%)\n4,680 (17%)\n5,320 (16%)\n3,495 (15%)\n4,875 (15%)\n&lt;0.001\n\n\nCancer\n201,640 (99%)\n38,010 (99%)\n49,190 (99%)\n27,060 (99%)\n33,595 (99%)\n23,090 (98%)\n30,695 (97%)\n&lt;0.001\n\n\nCerebrovascular disease\n6,730 (3.3%)\n1,285 (3.4%)\n1,870 (3.8%)\n930 (3.4%)\n1,115 (3.3%)\n650 (2.8%)\n880 (2.8%)\n0.007\n\n\nChronic kidney disease\n31,595 (15%)\n5,085 (13%)\n6,425 (13%)\n4,235 (16%)\n5,305 (16%)\n3,905 (17%)\n6,640 (21%)\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n38,585 (19%)\n5,520 (14%)\n10,095 (20%)\n4,010 (15%)\n6,130 (18%)\n4,730 (20%)\n8,100 (26%)\n&lt;0.001\n\n\nDiabetes\n56,340 (28%)\n7,220 (19%)\n6,050 (12%)\n7,575 (28%)\n11,790 (35%)\n9,385 (40%)\n14,320 (45%)\n&lt;0.001\n\n\nDementia\n7,385 (3.6%)\n1,875 (4.9%)\n2,910 (5.9%)\n1,000 (3.7%)\n720 (2.1%)\n410 (1.7%)\n470 (1.5%)\n&lt;0.001\n\n\nHeart failure\n28,735 (14%)\n3,870 (10%)\n5,665 (11%)\n3,465 (13%)\n4,645 (14%)\n3,680 (16%)\n7,410 (23%)\n&lt;0.001\n\n\nHypertension\n121,920 (60%)\n20,005 (52%)\n21,815 (44%)\n17,010 (62%)\n23,110 (68%)\n16,860 (72%)\n23,120 (73%)\n&lt;0.001\n\n\nHyperlipidemia\n67,435 (33%)\n10,355 (27%)\n10,390 (21%)\n9,765 (36%)\n14,650 (43%)\n10,245 (44%)\n12,030 (38%)\n&lt;0.001\n\n\nMyocardial infarction\n12,230 (6.0%)\n1,970 (5.2%)\n2,685 (5.4%)\n1,785 (6.5%)\n2,365 (6.9%)\n1,615 (6.9%)\n1,810 (5.7%)\n&lt;0.001\n\n\nPeripheral vascular disease\n13,180 (6.5%)\n2,420 (6.3%)\n3,535 (7.1%)\n1,720 (6.3%)\n2,270 (6.7%)\n1,555 (6.6%)\n1,680 (5.3%)\n&lt;0.001\n\n\nRheumatoid disease\n3,825 (1.9%)\n650 (1.7%)\n830 (1.7%)\n435 (1.6%)\n625 (1.8%)\n540 (2.3%)\n745 (2.4%)\n0.002\n\n\nValvular heart disease\n9,260 (4.5%)\n1,630 (4.3%)\n2,115 (4.3%)\n1,365 (5.0%)\n1,735 (5.1%)\n1,045 (4.5%)\n1,370 (4.3%)\n0.044\n\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Design-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "Impact of BMI on In-Hospital Outcomes in Colorectal Cancer Patients",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nNormal weight (BMI 20.0-24.9kg/m²) N = 38,2251\nUnderweight (BMI ≤19.9kg/m²) N = 49,6751\nOverweight (BMI 25.0-29.9kg/m²) N = 27,2951\nClass I obesity (BMI 30.0-34.9kg/m²) N = 34,0751\nClass II obesity (BMI 35.0-39.9kg/m²) N = 23,4651\nClass III obesity (BMI ≥40.0kg/m²) N = 31,5851\np-value2\n\n\n\n\nDied during hospitalization\n2,035 (5.3%)\n3,765 (7.6%)\n1,005 (3.7%)\n670 (2.0%)\n455 (1.9%)\n1,145 (3.6%)\n&lt;0.001\n\n\nLength of stay (days)\n6.0 (4.0, 11.0)\n6.0 (3.0, 11.0)\n6.0 (3.0, 11.0)\n5.0 (3.0, 8.0)\n5.0 (3.0, 8.0)\n5.0 (3.0, 9.0)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n60,660 (32,487, 114,574)\n56,083 (29,423, 110,997)\n67,339 (35,059, 120,194)\n67,317 (39,405, 115,412)\n67,982 (39,782, 112,523)\n68,570 (39,024, 125,641)\n&lt;0.001\n\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Impact of BMI on In-Hospital Outcomes in Colorectal Cancer Patients",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR1\n95% CI1\np-value\n\n\n\n\nBMI category\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Underweight (BMI ≤19.9kg/m²)\n1.52\n1.32, 1.73\n&lt;0.001\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n0.76\n0.64, 0.92\n0.004\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n0.47\n0.38, 0.58\n&lt;0.001\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n0.49\n0.38, 0.62\n&lt;0.001\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n0.91\n0.76, 1.10\n0.3\n\n\nAge, y\n1.02\n1.01, 1.03\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.15\n1.04, 1.28\n0.007\n\n\nRace\n\n\n\n\n\n\n\n\n    Asian or Pacific Islander\n—\n—\n\n\n\n\n    Black\n0.84\n0.65, 1.10\n0.2\n\n\n    Hispanic\n0.77\n0.58, 1.02\n0.072\n\n\n    Native American\n1.19\n0.63, 2.26\n0.6\n\n\n    Other\n1.07\n0.76, 1.52\n0.7\n\n\n    White\n0.73\n0.57, 0.93\n0.011\n\n\nIncome quartile\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.88\n0.77, 1.01\n0.060\n\n\n    $66,000 - $87,999\n0.89\n0.78, 1.03\n0.11\n\n\n    $88,000 or more\n0.85\n0.74, 0.99\n0.032\n\n\nInsurance payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n1.05\n0.87, 1.25\n0.6\n\n\n    Other\n1.42\n1.11, 1.82\n0.005\n\n\n    Private\n1.21\n1.01, 1.45\n0.037\n\n\nCharlson comorbidity index\n1.25\n1.22, 1.28\n&lt;0.001\n\n\nCardiac arrhythmia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.69\n1.50, 1.90\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.73\n0.64, 0.84\n&lt;0.001\n\n\nCancer\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.37\n0.25, 0.57\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.40\n1.13, 1.75\n0.002\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.67\n0.57, 0.78\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.85\n0.74, 0.97\n0.014\n\n\nDiabetes\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.78\n0.68, 0.90\n&lt;0.001\n\n\nDementia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.90\n0.72, 1.13\n0.4\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.33\n1.15, 1.55\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.82\n0.73, 0.92\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.63\n0.55, 0.71\n&lt;0.001\n\n\nMyocardial infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.08\n0.89, 1.32\n0.4\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.04\n0.86, 1.25\n0.7\n\n\nRheumatoid disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.77\n0.53, 1.14\n0.2\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.76\n0.60, 0.97\n0.030\n\n\n\n1 OR = Odds Ratio, CI = Confidence Interval"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "Impact of BMI on In-Hospital Outcomes in Colorectal Cancer Patients",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI1\np-value\n\n\n\n\nBMI category\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Underweight (BMI ≤19.9kg/m²)\n0.19\n-0.09, 0.47\n0.2\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n-0.11\n-0.40, 0.19\n0.5\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n-1.3\n-1.6, -1.1\n&lt;0.001\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n-1.5\n-1.8, -1.2\n&lt;0.001\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n-0.42\n-0.75, -0.09\n0.013\n\n\nAge, y\n0.00\n-0.01, 0.01\n0.5\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.12\n-0.04, 0.29\n0.14\n\n\nRace\n\n\n\n\n\n\n\n\n    Asian or Pacific Islander\n—\n—\n\n\n\n\n    Black\n-0.03\n-0.62, 0.57\n&gt;0.9\n\n\n    Hispanic\n-0.37\n-0.97, 0.23\n0.2\n\n\n    Native American\n-0.29\n-1.9, 1.3\n0.7\n\n\n    Other\n0.47\n-0.40, 1.3\n0.3\n\n\n    White\n-0.71\n-1.3, -0.16\n0.011\n\n\nIncome quartile\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n-0.11\n-0.32, 0.11\n0.3\n\n\n    $66,000 - $87,999\n0.06\n-0.18, 0.29\n0.6\n\n\n    $88,000 or more\n0.11\n-0.15, 0.38\n0.4\n\n\nInsurance payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n-0.88\n-1.2, -0.51\n&lt;0.001\n\n\n    Other\n-0.74\n-1.2, -0.26\n0.003\n\n\n    Private\n-1.1\n-1.4, -0.79\n&lt;0.001\n\n\nCharlson comorbidity index\n0.10\n0.05, 0.14\n&lt;0.001\n\n\nCardiac arrhythmia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.9\n1.7, 2.2\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.92\n0.70, 1.1\n&lt;0.001\n\n\nCancer\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-6.8\n-8.7, -4.9\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.6\n0.98, 2.1\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.36\n0.07, 0.64\n0.013\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.06\n-0.28, 0.15\n0.6\n\n\nDiabetes\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.12\n-0.34, 0.11\n0.3\n\n\nDementia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.56\n0.09, 1.0\n0.020\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.99\n0.69, 1.3\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.47\n-0.67, -0.26\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.75\n-0.92, -0.57\n&lt;0.001\n\n\nMyocardial infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.24\n-0.58, 0.10\n0.2\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.32\n-0.08, 0.71\n0.12\n\n\nRheumatoid disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.06\n-0.59, 0.47\n0.8\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.06\n-0.49, 0.37\n0.8\n\n\n\n1 CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI1\np-value\n\n\n\n\nBMI category\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Underweight (BMI ≤19.9kg/m²)\n1,982\n-1,962, 5,926\n0.3\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n4,581\n244, 8,917\n0.038\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n3,228\n-654, 7,110\n0.10\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n2,630\n-1,747, 7,008\n0.2\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n16,529\n11,667, 21,391\n&lt;0.001\n\n\nAge, y\n-167\n-349, 14\n0.071\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n3,357\n780, 5,934\n0.011\n\n\nRace\n\n\n\n\n\n\n\n\n    Asian or Pacific Islander\n—\n—\n\n\n\n\n    Black\n-26,578\n-36,041, -17,115\n&lt;0.001\n\n\n    Hispanic\n-1,029\n-10,691, 8,633\n0.8\n\n\n    Native American\n-32,390\n-51,526, -13,254\n&lt;0.001\n\n\n    Other\n5,536\n-10,834, 21,906\n0.5\n\n\n    White\n-30,608\n-39,306, -21,911\n&lt;0.001\n\n\nIncome quartile\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1,756\n-1,439, 4,950\n0.3\n\n\n    $66,000 - $87,999\n5,940\n2,214, 9,665\n0.002\n\n\n    $88,000 or more\n14,007\n9,423, 18,591\n&lt;0.001\n\n\nInsurance payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n-5,032\n-10,529, 466\n0.073\n\n\n    Other\n-12,494\n-18,748, -6,239\n&lt;0.001\n\n\n    Private\n-3,788\n-8,890, 1,315\n0.15\n\n\nCharlson comorbidity index\n-824\n-1,446, -202\n0.009\n\n\nCardiac arrhythmia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n26,334\n22,342, 30,326\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n7,277\n4,155, 10,398\n&lt;0.001\n\n\nCancer\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-113,531\n-149,726, -77,336\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n22,590\n12,804, 32,376\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2,133\n-2,000, 6,266\n0.3\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2,183\n-1,527, 5,894\n0.2\n\n\nDiabetes\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-87\n-3,188, 3,014\n&gt;0.9\n\n\nDementia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-2,130\n-8,203, 3,942\n0.5\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n13,742\n8,964, 18,520\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-6,253\n-9,328, -3,177\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-7,614\n-10,235, -4,993\n&lt;0.001\n\n\nMyocardial infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n5,823\n-626, 12,273\n0.077\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n8,090\n2,324, 13,857\n0.006\n\n\nRheumatoid disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1,854\n-9,989, 6,280\n0.7\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-500\n-6,877, 5,877\n0.9\n\n\n\n1 CI = Confidence Interval"
  }
]